| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/19/2009 | WO2009022821A2 Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same |
| 02/19/2009 | WO2009022756A1 Diagnosis and treatment of ischemic disease |
| 02/19/2009 | WO2009022740A1 Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as the active ingredient |
| 02/19/2009 | WO2009022731A1 P2x4 receptor antagonist |
| 02/19/2009 | WO2009022730A1 P2x4 receptor antagonist |
| 02/19/2009 | WO2009022722A1 Tricyclic amine compound |
| 02/19/2009 | WO2009022721A1 Tricyclic amide compound |
| 02/19/2009 | WO2009022720A1 Five-membered heterocyclic compound |
| 02/19/2009 | WO2009022687A1 Phenylacetic acid compound |
| 02/19/2009 | WO2009022674A1 Medical composition containing rebamipide |
| 02/19/2009 | WO2009022670A1 Quickly disintegrating tablet |
| 02/19/2009 | WO2009022642A1 Novel salt of isoquinoline compound and crystal thereof |
| 02/19/2009 | WO2009022633A1 Bicyclic acylguanidine derivative |
| 02/19/2009 | WO2009022477A1 Norbornene polymers bearing biologically active substances bonded thereto, proces for production of the same and use thereof |
| 02/19/2009 | WO2009022430A1 Skin whitening agent |
| 02/19/2009 | WO2009022424A1 Agent for exterminating pathogenic bacteria in fishes and method of exterminating the same |
| 02/19/2009 | WO2009022417A1 Peritoneal dialysate |
| 02/19/2009 | WO2009022355A1 Extended release compositions comprising mycophenolate sodium and processes thereof |
| 02/19/2009 | WO2009022354A2 Modified dosage forms of tacrolimus |
| 02/19/2009 | WO2009022346A2 Phenyl carbamates for treating gastrointestinal inflammation |
| 02/19/2009 | WO2009022345A1 Phenyl carbamates for the treatment of multiple sclerosis |
| 02/19/2009 | WO2009022339A1 Polypeptides, matrices, hydrogels and methods of using same for tissue regeneration and repair |
| 02/19/2009 | WO2009022328A2 Regulators of mmp-9 and uses therof |
| 02/19/2009 | WO2009022327A2 Novel process for preparing highly pure levocetirizine and salts thereof |
| 02/19/2009 | WO2009022311A2 1,2-diamido-ethylene derivatives as orexin antagonists |
| 02/19/2009 | WO2009022216A2 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles |
| 02/19/2009 | WO2009022215A1 Combination motif immune stimulatory oligonucleotides with improved activity |
| 02/19/2009 | WO2009022190A1 Delivery of drug combinations |
| 02/19/2009 | WO2009022185A2 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use |
| 02/19/2009 | WO2009022179A2 Glucokinase activators in the treatment of osteoarthritis |
| 02/19/2009 | WO2009022171A1 Pyridinyiioxy pyridines as alk5 inhibitors |
| 02/19/2009 | WO2009022169A1 Solid valsartan composition |
| 02/19/2009 | WO2009022168A1 Novel crystalline form |
| 02/19/2009 | WO2009022104A1 Fascaplysin derivatives and their use in the treatment of cancer |
| 02/19/2009 | WO2009022098A1 Amino acid derivatives |
| 02/19/2009 | WO2009022096A1 Drug combinations for the treatment of sialorrhoea |
| 02/19/2009 | WO2009022066A2 Novel naphthalene derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 02/19/2009 | WO2009022065A2 Novel naphthalene derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 02/19/2009 | WO2009022064A2 Novel naphthalene derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 02/19/2009 | WO2009022063A2 Novel naphthalene derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 02/19/2009 | WO2009022041A1 Ointment for controlling and treating skin diseases and preparation method therefor |
| 02/19/2009 | WO2009022009A1 Pharmaceutical composition comprising a pyrazole-o-glucoside derivative |
| 02/19/2009 | WO2009022008A1 Pharmaceutical composition comprising a pyrazole-o-glucoside derivative |
| 02/19/2009 | WO2009022007A1 Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative |
| 02/19/2009 | WO2009021992A2 Fused bicyclic pyrimidines |
| 02/19/2009 | WO2009021991A1 Use of r(+)-alpha-lipoic acid for cryptogenic neuropathy |
| 02/19/2009 | WO2009021990A1 Fused imidazoles for cancer treatment |
| 02/19/2009 | WO2009021980A1 α-ALKYL SUBSTITUTED N-ACYLTRYPTOPHANOLS |
| 02/19/2009 | WO2009021961A1 Pyrazoloquinoline and pyrazolonaphthyridine derivatives as gaba alpha ligands |
| 02/19/2009 | WO2009021957A2 Tricyclic heterocyclic compounds as gaba a modulators |
| 02/19/2009 | WO2009021887A1 Substituted hydantoins |
| 02/19/2009 | WO2009021869A1 Pyrazolo[3,4-d]-pyramidine derivatives as antiproliferative agents |
| 02/19/2009 | WO2009021808A1 Increasing the efficiency of utilization of ingested creatine |
| 02/19/2009 | WO2009021747A2 Treatment of duchenne muscular dystrophy |
| 02/19/2009 | WO2009021735A1 Increased creatine retention with soluble fibres |
| 02/19/2009 | WO2009021696A1 Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors |
| 02/19/2009 | WO2009021656A2 Tablet containing donepezile hydrochloride in amorphous form |
| 02/19/2009 | WO2009021622A1 Extracts with liver-x-receptor modulators, compounds and their use especially in weight control |
| 02/19/2009 | WO2009021526A1 Hyaluronic acid dispersion, production and use |
| 02/19/2009 | WO2009021521A2 Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression |
| 02/19/2009 | WO2009021404A1 (1s, 2s, 3s, 4r)-3-[(1s)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2- hydroxyl-cyclopentyl-1-carboxylic acid hydrates and pharmaceutical uses thereof |
| 02/19/2009 | WO2009021357A1 Cooling agent composition and preparative method thereof |
| 02/19/2009 | WO2009021325A1 Microrna compositions and methods for the treatment of myelogenous leukemia |
| 02/19/2009 | WO2009021323A1 Dhea compositions for treating menopause |
| 02/19/2009 | WO2009009378A3 Cathepsin-d neuroprotection |
| 02/19/2009 | WO2009006299A3 Multi-particulate systems |
| 02/19/2009 | WO2009006245A3 Calcilytic compounds |
| 02/19/2009 | WO2009006141A3 Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof |
| 02/19/2009 | WO2009005794A3 Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders |
| 02/19/2009 | WO2009004440A3 Quick dissolve compositions of memantine hydrochloride |
| 02/19/2009 | WO2009003024A3 High shear process for aspirin production |
| 02/19/2009 | WO2009001040A3 Treatment of depression |
| 02/19/2009 | WO2009000552A3 Compositions for the treatment of hyperphenylalaninemia |
| 02/19/2009 | WO2008157711A3 Materials comprising water-soluble polymer particles and methods of making and using them |
| 02/19/2009 | WO2008157408A3 Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity |
| 02/19/2009 | WO2008157407A3 Thiadiazole, oxadiazole and triazole derivatives for treating leukemia |
| 02/19/2009 | WO2008157404A3 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| 02/19/2009 | WO2008157288A3 A baclofen solution for low-volume therapeutic delivery |
| 02/19/2009 | WO2008157272A3 Deuterium-enriched tamsulosin |
| 02/19/2009 | WO2008157205A3 Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp |
| 02/19/2009 | WO2008156656A3 Method for making biaryl compounds, compounds made by the method, and method for their use |
| 02/19/2009 | WO2008156629A3 Methods and agents for inhibiting tumor growth by targeting the ssdna replication intermediate of tumor stem cells |
| 02/19/2009 | WO2008156513A3 Methods to protect skeletal muscle against injury |
| 02/19/2009 | WO2008155651A3 Inositol for induction of ovulation |
| 02/19/2009 | WO2008155533A3 Phenothiazine compounds for treating mild cognitive impairment |
| 02/19/2009 | WO2008155520A3 4-hydroxy benzoate derivatives for use in the treatment of infection, inflammation or pain |
| 02/19/2009 | WO2008154246A8 Hiv integrase inhibitors |
| 02/19/2009 | WO2008153937A3 Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| 02/19/2009 | WO2008152423A3 Treatment of inflammation or autoimmune diseases with sulphated compounds |
| 02/19/2009 | WO2008149382A8 Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
| 02/19/2009 | WO2008148967A3 Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same |
| 02/19/2009 | WO2008144320A3 Opioid and methods of making and using the same |
| 02/19/2009 | WO2008140507A9 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
| 02/19/2009 | WO2008137862A3 Methods of using mir34 as a biomarker for tp53 functional status |
| 02/19/2009 | WO2008137148A3 Methods and compositions for treating pulmonary hypertension |
| 02/19/2009 | WO2008130630A3 Polymorphic form of rimonabant hydrochloride and processes for preparation thereof |
| 02/19/2009 | WO2008130600A3 Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| 02/19/2009 | WO2008130449A3 Modulators of amyloid-beta production |
| 02/19/2009 | WO2008127361A3 Synthesis of enone intermediate |
| 02/19/2009 | WO2008126756A9 Seleniferous compound and, containing the same, plant and nutritional supplement |